Five weeks after its declaration, the Ebola Bundibugyo outbreak in the Democratic Republic of Congo remains far from controlled. While the response has undoubtedly intensified, the virus continues to outpace efforts, crossing borders and claiming lives.

Escalating response efforts

Significant progress has been made. Patient capacity has surged from fewer than 10 beds to over 500 across 19 health centers in affected zones. Testing has scaled similarly: from 30 daily tests at the outbreak’s start to more than 2,000 now conducted daily across nine labs covering three provinces. Over 100 recoveries have been recorded, proving that early intervention saves lives.

Yet the toll remains severe: 1,094 confirmed cases and 277 deaths to date. According to WHO Director-General Tedros Adhanom Ghebreyesus, the outbreak continues to outpace the response. Contact tracing remains inadequate, isolation capacity lags behind needs, and safe burials remain a daily challenge in communities often distrustful or inaccessible.

Cross-border spread raises global alarm

The epidemic has now spread beyond DRC’s Ituri, North Kivu, and South Kivu provinces. Neighboring Uganda reports 20 confirmed cases and two deaths, all linked to the Congolese strain. More alarmingly, France confirmed its first case on European soil this Wednesday: a humanitarian doctor with ALIMA NGO, returning from DRC, tested positive for Ebola Bundibugyo. Receiving treatment in a specialized facility, the patient is currently stable. An epidemiological investigation is underway to identify and monitor contacts.

This case underscores the sacrifices of frontline workers. Nearly 80 health workers have been infected since the crisis began, prompting WHO to urge states to ensure secure deployment conditions for humanitarian personnel, including rapid medical evacuation options in case of contamination.

Structural hurdles hinder containment

Beyond health challenges, the response faces structural barriers complicating every intervention. Border closures impede team and equipment movement. Security incidents multiply in a region plagued by decades of armed conflict. Funding remains insufficient despite WHO and Africa CDC launching a continental plan totaling $518 million.

One glimmer of hope: a clinical trial evaluating two antivirals, MBP134 and remdesivir, begins next week in DRC. Led by a consortium including the Congolese National Institute of Biomedical Research, ALIMA NGO, Oxford University, and WHO—with support from U.S. donations and Gilead Sciences—the trial could mark a turning point in combating an epidemic that, five weeks after its onset, shows no signs of containment.